These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37663034)

  • 1. Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis.
    Rudwaleit M; Machado PM; Taieb V; de Peyrecave N; Hoepken B; Gensler LS
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189079. PubMed ID: 37663034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
    Osterhaus JT; Purcaru O
    Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study.
    van der Heijde D; Braun J; Rudwaleit M; Purcaru O; Kavanaugh AF
    RMD Open; 2018; 4(1):e000659. PubMed ID: 29670761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.
    Tillett W; Coates LC; Kiri S; Taieb V; Willems D; Mease PJ
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221140846. PubMed ID: 36533099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.
    Navarro-Compán V; Ramiro S; Deodhar A; Mease PJ; Rudwaleit M; de la Loge C; Fleurinck C; Taieb V; Mørup MF; Massow U; Kay J; Magrey M
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
    van der Heijde D; Joshi A; Pangan AL; Chen N; Betts K; Mittal M; Bao Y
    Rheumatology (Oxford); 2016 Jan; 55(1):80-8. PubMed ID: 26316575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
    Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
    Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
    Braun J; Baraliakos X; Hermann KG; Landewé R; Machado PM; Maksymowych WP; Davies O; Hoepken B; Nurminen T; Stach C; van der Heijde D
    RMD Open; 2017; 3(1):e000430. PubMed ID: 28848654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.
    Rudwaleit M; Marzo-Ortega H; Navarro-Compán V; Tham R; Kumke T; Bauer L; de Peyrecave N; Kim M; Van den Bosch F
    RMD Open; 2024 Aug; 10(3):. PubMed ID: 39209369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.
    Landewé R; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch F; Gaffney K; Bauer L; Hoepken B; de Peyrecave N; Thomas K; Gensler LS
    Rheumatol Ther; 2020 Sep; 7(3):581-599. PubMed ID: 32529495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort).
    van Lunteren M; Ez-Zaitouni Z; Fongen C; Landewé R; Ramonda R; van der Heijde D; van Gaalen FA
    Rheumatology (Oxford); 2017 Dec; 56(12):2222-2228. PubMed ID: 29155961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.
    Rudwaleit M; Deodhar A; Bauer L; Gensler L; Hoepken B; Kumke T; Auteri SE; Kim M; Maksymowych W
    RMD Open; 2024 May; 10(2):. PubMed ID: 38724259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
    Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
    Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels.
    Tam HKJ; Nash P; Robinson PC
    ACR Open Rheumatol; 2021 Oct; 3(10):699-706. PubMed ID: 34405589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-sectional study on factors associated with poor work outcomes in patients with axial spondyloarthritis in Singapore.
    Goh Y; Kwan YH; Leung YY; Fong W; Cheung PP
    Int J Rheum Dis; 2019 Nov; 22(11):2001-2008. PubMed ID: 31576680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study.
    Dougados M; van der Heijde D; Tsai WC; Saaibi D; Marshall L; Jones H; Pedersen R; Vlahos B; Tarallo M
    Health Qual Life Outcomes; 2020 Jan; 18(1):4. PubMed ID: 31900174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons.
    Akkoç N; Arteaga CH; Auteri SE; Betts M; Fahrbach K; Kim M; Kiri S; Neupane B; Gaffney K; Mease PJ
    Rheumatol Ther; 2023 Apr; 10(2):307-327. PubMed ID: 36633815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
    van der Heijde D; Deodhar A; Fleischmann R; Mease PJ; Rudwaleit M; Nurminen T; Davies O
    Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1030-1039. PubMed ID: 27696727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.